Clinical trial: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Status: ACTIVE_NOT_RECRUITING
Conditions: Fallopian Tube Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Platinum-Refractory Fallopian Tube Carcinoma|Platinum-Refractory Ovarian Carcinoma|Platinum-Refractory Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Mucinous Adenocarcinoma|Recurrent Fallopian Tube Transitional Cell Carcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent Ovarian Low Grade Serous Adenocarcinoma|Recurrent Ovarian Mucinous Adenocarcinoma|Recurrent Ovarian Seromucinous Carcinoma|Recurrent Ovarian Transitional Cell Carcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Transitional Cell Carcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma|Refractory Fallopian Tube Clear Cell Adenocarcinoma|Refractory Fallopian Tube Endometrioid Adenocarcinoma|Refractory Fallopian Tube High Grade Serous Adenocarcinoma|Refractory Fallopian Tube Mucinous Adenocarcinoma|Refractory Fallopian Tube Transitional Cell Carcinoma|Refractory Fallopian Tube Undifferentiated Carcinoma|Refractory Low Grade Fallopian Tube Serous Adenocarcinoma|Refractory Ovarian Clear Cell Adenocarcinoma|Refractory Ovarian Endometrioid Adenocarcinoma|Refractory Ovarian High Grade Serous Adenocarcinoma|Refractory Ovarian Low Grade Serous Adenocarcinoma|Refractory Ovarian Mucinous Adenocarcinoma|Refractory Ovarian Seromucinous Carcinoma|Refractory Ovarian Transitional Cell Carcinoma|Refractory Ovarian Undifferentiated Carcinoma|Refractory Primary Peritoneal Clear Cell Adenocarcinoma|Refractory Primary Peritoneal Endometrioid Adenocarcinoma|Refractory Primary Peritoneal High Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Transitional Cell Carcinoma|Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions: PROCEDURE: Biospecimen Collection|DRUG: Cediranib Maleate|PROCEDURE: Computed Tomography|PROCEDURE: Computed Tomography with Contrast|BIOLOGICAL: Durvalumab|PROCEDURE: Echocardiography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|DRUG: Olaparib|DRUG: Paclitaxel|DRUG: Pegylated Liposomal Doxorubicin Hydrochloride|DRUG: Topotecan Hydrochloride
Study Type: INTERVENTIONAL
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT